Background and Purpose-Alterations of neuroangiogenic response play important roles in the development of aging-related neurodisorders and affect gene-based therapies. We tested brain response to vascular endothelial growth factor (VEGF) in aged mice. Methods-Adeno-associated viral vector (AAV)-VEGF, an adeno-associated viral vector expressing VEGF, was injected into the brain of 3-, 12-, and 24-month-old mice. AAV-LacZ-injected mice were used as controls (nϭ6). Before euthanasia at 6 weeks after vector injection, the mice were intraperitoneally injected with 5-bromodeoxyuridine for 3 consecutive days. The vascular density and the number of neuroprogenitors were analyzed.
V ascular endothelial growth factor (VEGF) is a promising candidate gene for the treatment of ischemic stroke because it mediates both angiogenesis and neurogenesis. 1 VEGF exerts its mitogenic, neurogenic, and angiogenic effects mainly through VEGF receptor-2 (VEGFR-2). 2, 3 VEGF expression is increased during cerebral ischemia in both patients and experimental animals. 4, 5 However, endogenous VEGF does not appear to be sufficient to completely protect the brain from ischemic injury. Interestingly, many in vivo preclinical studies have shown that exogenous administration of VEGF-induced angiogenic changes in the ischemic brain results in a reduction of ischemic injury and better functional outcomes. 6, 7 We have shown that adeno-associated viral vector (AAV)-mediated VEGF gene transfer induces angiogenesis in the mouse brain and reduces ischemic brain injury caused by transient middle cerebral artery occlusion. 8 -10 Thus, overexpression of VEGF is a promising strategy for the treatment of ischemic brain injury.
There is accumulating evidence suggesting that aging affects both angiogenesis and vasculogenesis. [11] [12] [13] Angiogenesis responsible for collateral development in limb ischemia is impaired with aging. 14 Aging also affects vascularization during fracture repair. 15 Reduced angiogenic activity in the elderly is mostly associated with a reduction in VEGF expression in response to injury attributed to varying mechanisms such as low promoter activity 14 or reduced upstream signaling, eg, HIF1-␣. 15 In vitro studies have suggested that aged endothelial cells show impaired proliferation and migration in response to other important angiogenic-related signals such as platelet-derived growth factor and fibroblast growth factor. 16, 17 Stroke occurs mostly in the elderly population. It is important to know if brain responsiveness to VEGF is affected by advancing age. In this study, we chose AAV serotype 1 to mediate VEGF gene transfer to compare the angiogenic and neurogenic responses of the mouse brain in 3 age groups because AAV1 has been successfully used to deliver therapeutic genes into the brain. 8 We used 3-, 12-, and 24-month-old mice to represent young, middle-aged, and aged individuals. We found that angiogenic and neurogenic responses to VEGF stimulation were attenuated in the aged mouse brain.
Methods and Materials Animals
All animal procedures were carried out according to a protocol approved by the Institutional Animal Care and Use Committee of the University of California, San Francisco. C57BL/6J mice (The Jackson Laboratory; Bar Harbor, Maine) weighing 30 to 35 g, aged 3, 12, and 24 months, were used.
AAV Vector Construction and Production
The AAV-VEGF and AAV-LacZ were constructed as previously described. 18 AAV vectors were produced using the 3 plasmid cotransfection system 19 and purified by CsCl 2 centrifugation. Viral titers were determined by dot blot analysis of DNA content and expressed as genome copies.
Injection of AAV Vectors Into the Mouse Brain
Two microliters of viral suspensions containing 2ϫ10 9 genome copies of viruses were injected into the caudate putamen as described previously. 8 
Histological Analysis
5-Bromodeoxyuridine (BrdU; Sigma), a thymidine analog, was injected intraperitoneally twice daily, 100 mg/kg, for 3 consecutive days before the animals were euthanized 6 weeks after vector injection. Mouse brains were perfusion-fixed with 4% paraformaldehyde, embedded in paraffin, and sectioned (6 m in thickness). Capillary density was analyzed as described previously. 8 For immunostaining of BrdU-positive cells, sections were treated with 2 mol/L HCl at 37°C for 30 minutes and rinsed in 0.1 mol/L boric acid (pH 8.5) at room temperature for 10 minutes before being treated with the following procedures. Sections were incubated in 0.3% H 2 O 2 in methanol for 30 minutes to quench the endogenous peroxidase activity and heated up to 95°C for 15 minutes in 10 mmol/L sodium citrate buffer, pH 6.0, for antigen retrieval. The immunohistochemical staining was done using the protocol of standard Elite Vectastain ABC Kit (Vector Laboratories) using primary antibodies listed in the Table, including doublecortin (DCX), VEGFR2, CD31, CD68, and BrdU.
BrdU-, VEGFR-2-, and DCX-immunopositive cells were counted blindly around the needle track and in the subventricular zone (SVZ) under a microscope with 40ϫ objective lens. The data were expressed as meanϮSD per section, and 3 sections were counted for each animal.
Western Blot Analysis
Proteins were isolated from the needle injection site, separated in 14% of Tris-glycine gel, and electrotransferred onto a nitrocellulose membrane (Bio-Rad Laboratories). After blocking in 5% milk, the membrane was incubated overnight with rabbit antimouse VEGF antibody (1:200; Santa Cruz Biotechnology) at 4°C. After incubating with horseradish peroxidase conjugated antirabbit secondary antibody (Amersham, Buckinghamshire, UK) diluted at 1:10 000 and reacting with FEMO detection reagent (Pierce Biotechnology), the membrane was exposed to Kodak film.
Statistical Analysis
All data are presented as meanϮSD and were compared using one-way analysis of variance followed by post hoc t test least significant differences. A probability value of Ͻ5% was considered statistically significant.
Results

AAV-Mediated Gene Transfer Not Affected by Animal Age
To examine the gene transduction efficiency mediated by AAV-LacZ or AAV-VEGF, LacZ and VEGF gene expressions were analyzed using immunostaining. We detected LacZ and VEGF expression around the injection sites in all the animals. Similar transgene expression among all the age groups suggests that age, per se, does not affect gene transduction efficiency (Figure 1 ; to view the figure in color, please see the Supplemental Figure II , available online at http://stroke.ahajournals.org).
Attenuated Angiogenic Response to VEGF Overexpression in the Brain of Aged Mice
To analyze if AAV-VEGF induces a similar degree of angiogenesis in the brain of mice in the different age groups, capillaries were quantified on lectin-stained sections. As shown in Figure 2 (to view the figure in color, please see Supplemental Figure III , available online at http://stroke. 
VEGF Overexpression Did Not Induce VEGFR-2 Expression in 24-Month-Old Mice
To study whether attenuated angiogenesis and neurogenesis in the aged brain in response to VEGF stimulation are due to the decrease of VEGF receptor functions, we performed Western blot analysis. We found that VEGFR-2 expression was increased 6 weeks after AAV-VEGF injection in the brain of 3-and 12-month-old mice. However, this increase was attenuated in the brain of 24-month-old mice ( Figure 5 ). The expression of VEGFR-1 was the same in the 3 groups with or without AAV-VEGF injection (data not shown). Thus, overexpression of VEGF in the brain of old mice did not upregulate VEGFR-2 expression.
We further analyzed the number of VEGFR-2-positive endothelial cells after VEGF stimulation. We found more VEGFR-2-positive endothelial cells in the AAV-VEGFinjected brain of 3-and 12-month-old mice, although the increase did not reach statistical significance with the sample size we used 
Discussion
In the present study, we demonstrated that: (1) AAV1-mediated overexpression of VEGF in the normal adult mouse brain induced angiogenesis and neurogenesis; (2) the angiogenic and neurogenic responses to VEGF stimulation in the brain of 24-month-old mice were attenuated; and (3) overexpression of VEGF upregulated VEGFR-2 expression in the brain of 3-and 12-month-old mice, but not in 24-month-old mice. Although advanced age does not preclude augmentation of collateral vessel development in the ischemic limb in response to exogenous angiogenic cytokines, 14 we found that AAV-mediated VEGF gene transfer resulted in less angiogenesis and neurogenesis in the normal brain of aged mice. Our results also suggest that changes in VEGF receptor expression or function may contribute to the reduced responses of the aged brain to VEGF stimulation.
Angiogenesis and neurogenesis are prominent features of neurological disease either as pathophysiological factors or as responses to injury. 1 One common thread that connects angiogenesis, neurogenesis, and pathogenesis is VEGF, which has been identified on the basis of its vascular effects but recognized as an important signaling molecule in neural tissue as well. Recent insights into the role of VEGF in a variety of neurological disorders, including stroke and motor neuron disease, suggest that VEGF or its downstream effectors may be promising therapeutic targets for these diseases.
Recent studies indicate that VEGF can stimulate neurogenesis. VEGF increases the incorporation of BrdU into cells expressing immature neuronal markers both in mouse cortical cultures in vitro and in the SVZ and subgranular zone of the adult rat brain in vivo. 20, 21 VEGFR-2 is implicated in each of these cases. Because neural stem cells from the hippocampus of adult rats express VEGF and its receptors, 22 transient forebrain ischemia-induced cell proliferation and differentiation in the dentate gyrus may be mediated by enhanced VEGF receptor intracellular signaling pathways. 23 All of these facts suggest that VEGF receptors in the early period of reperfusion may contribute to neurogenesis rather than angiogenesis in the hippocampal dentate gyrus. 24 We found that expression of VEGFR-2 was upregulated after injection of AAV-VEGF into the mouse brain. There was no increase of VEGFR-2 expression in the brain of 24-month-old mice after AAV-VEGF injection, suggesting that functional VEGFR-2 signaling may be reduced in the aged mouse brain. A recent study indicates that with advancing age, impairment of VEGFR-2/PI3-kinase signaling contributes to the reduction of flow-induced vasodilation in coronary arterioles. 25 By ligating the femoral artery unilaterally in mice, Qian et al 26 found that ischemia led to an increase in the expression of VEGFR-2 in younger endothelial nitric oxide synthase-deficient mice; however, this increase in VEGFR-2 expression was absent in the older endothelial nitric oxide synthase knockout animals, which was followed by the severe disease phenotype. Taken together, reduction of VEGFR-2 expression or function may contribute to the reduced angiogenic and neurogenic responses of the older brain to VEGF stimulation.
This study has several limitations. We only tested one virus dose because our previous study showed that this dose effectively induced angiogenesis in the young mouse brain. 8 It is possible that the aged brain requires a higher viral load to be effective. VEGFR-2 expression in the brain of 24-month-old mice was not upregulated by our chosen dose of AAV-VEGF. The phosphorylation of VEGFR-2 and the activities of VEGFR-2 downstream genes were not studied. The roles of other factors such as caveolin-1 27 that influence VEGFR-2 functions were not analyzed. We have examined the effect of aging on the VEGF response in the normal mouse brain. The responses and regulation of receptors are likely different and one cannot simply infer that similar changes would take place during ischemia. Future studies will need to address these issues.
In summary, we have shown in this study that angiogenic and neurogenic responses to VEGF stimulation are reduced in the brain of aged mice. Our data also suggest that reduced VEGFR-2 quantity or function may be a potential mechanism for the diminished response of the aged brain to VEGF stimulation.
